How to Get Vyleesi in New York: Prescriptions, Telehealth, and Pharmacy Guide

What Is Vyleesi and Who Qualifies for It in New York?

Vyleesi is the brand name for bremelanotide, a melanocortin receptor agonist approved by the FDA in June 2019 for acquired, generalized HSDD in premenopausal women. Qualification requires a documented pattern of low sexual desire causing personal distress, with no adequate medical or psychiatric explanation. New York clinicians follow the same federal indication criteria set out in the Vyleesi prescribing information.

The RECONNECT program consisted of two replicate Phase 3 randomized controlled trials (N=1,267 combined) published in Obstetrics and Gynecology in 2019. In those trials, significantly more women receiving bremelanotide 1.75 mg met the co-primary endpoints of a clinically meaningful increase in sexual desire and a decrease in distress compared with placebo (P<0.001 for both endpoints) [1]. The number-needed-to-treat for a meaningful desire response was approximately 7. Those efficacy data support the diagnostic threshold New York prescribers use when evaluating candidates.

The FDA label explicitly restricts the indication to premenopausal women and excludes use for HSDD caused by relationship problems, a co-existing medical condition that has not been treated, or a medication with a known side effect of reduced libido [2]. A New York clinician will screen for each of these exclusions at intake.

How to Get a Vyleesi Prescription in New York: Step by Step

Getting a prescription follows a clear sequence. Complete an online or in-office intake, attend a synchronous or asynchronous clinical visit, receive an electronic prescription, and arrange pharmacy fulfillment. Telehealth shortens total time to prescription to roughly 30-60 minutes of active patient time.

Step 1: Choose a prescriber. In New York, MD, DO, NP, and PA clinicians with full prescriptive authority may prescribe Vyleesi. There is no requirement for the prescriber to be an OB-GYN, although many women prefer a specialist given the sexual-medicine context. A HealthRX clinician can evaluate New York residents via a HIPAA-compliant video or asynchronous visit.

Step 2: Complete a validated HSDD screening tool. The Female Sexual Function Index (FSFI) and the Decreased Sexual Desire Screener (DSDS) are the two instruments most commonly used in New York practices [3]. A score consistent with acquired, generalized HSDD is documented in the chart and supports medical necessity for insurance purposes.

Step 3: Rule out contributing conditions. The clinician reviews current medications, thyroid status, and mental health history. No specific blood panel is mandated by the FDA label for bremelanotide, but many New York prescribers order TSH, free T4, and a basic metabolic panel to exclude reversible causes. Cardiovascular contraindications (uncontrolled hypertension, established cardiovascular disease) are screened via blood pressure measurement and history, because bremelanotide transiently raises mean blood pressure by approximately 1-3 mmHg for up to 12 hours after each dose [2].

Step 4: Electronic prescription to your chosen pharmacy. Once approved, the clinician sends an e-prescription to a retail, specialty, or compounding pharmacy in New York. If you are using insurance, a prior authorization request is submitted simultaneously.

Step 5: Receive and self-administer. The autoinjector arrives pre-loaded with 1.75 mg. Inject subcutaneously into the abdomen, thigh, or upper arm 45 minutes before sexual activity. Dispose of the device in an approved sharps container.

Vyleesi Telehealth Prescribing in New York

New York permits telehealth prescribing of Vyleesi. Telehealth visits are legal for this indication under New York Public Health Law and the state's ongoing telehealth parity framework, which requires insurers to reimburse telehealth at the same rate as in-person visits [4]. Prescribers must hold an active New York state license and must establish a valid patient-provider relationship before issuing a prescription, consistent with guidance from the New York State Department of Health [5].

Synchronous video is the most common modality. Asynchronous (store-and-forward) encounters are permitted in New York for certain specialties, though most Vyleesi prescribers prefer live video to allow real-time blood pressure assessment and validated questionnaire review.

From initial intake to prescription, telehealth typically cuts the timeline to one to two business days. Pharmacy processing adds two to five more business days for shipping, bringing the realistic door-to-door window to three to seven business days for most New York residents.

The HealthRX New York HSDD Telehealth Pathway uses a three-gate model: Gate 1 confirms the premenopausal status and DSDS positivity; Gate 2 rules out cardiovascular contraindications using a validated blood-pressure self-report and medication review; Gate 3 documents personal distress using the Female Sexual Distress Scale-Revised (FSDS-R) cutoff score of 11 or higher [6]. Patients who clear all three gates in the asynchronous intake proceed to a five-minute synchronous video confirmation before the prescription is sent. This model reduces unnecessary synchronous visit time by an estimated 40% compared with a fully synchronous workflow, based on internal HealthRX scheduling data.

What Labs Are Required Before Vyleesi in New York?

No laboratory tests are federally mandated before starting bremelanotide. The FDA prescribing information does not list a required pre-treatment lab panel [2]. Standard-of-care practice in New York sexual-medicine clinics typically includes the following assessments.

A thyroid panel (TSH, free T4) rules out hypothyroidism, which independently suppresses libido and may account for the entire clinical picture. The American Thyroid Association recommends TSH screening in symptomatic women at any age [7]. A fasting lipid panel and basic metabolic panel are ordered when the clinical history suggests metabolic syndrome, a known contributor to HSDD. Testosterone (total and free) and SHBG levels are ordered selectively; although androgen insufficiency is not the FDA-approved indication, low androgens often co-exist with HSDD and may influence response [8].

Blood pressure must be documented before each dose is administered at home. The Vyleesi label contraindicates use in women with cardiovascular disease or uncontrolled hypertension [2]. A resting BP above 130/80 mmHg warrants further evaluation before prescribing, per the American Heart Association's 2017 hypertension guidelines [9].

Insurance Coverage and Prior Authorization in New York

New York Medicaid covers bremelanotide with prior authorization for eligible premenopausal women diagnosed with HSDD. The prior authorization process requires documentation of the HSDD diagnosis (ICD-10 code F52.0), evidence of personal distress (FSDS-R or equivalent score), confirmation of premenopausal status, and attestation that the desire disorder is not attributable to another treatable condition or a medication side effect [10].

Commercial insurers in New York vary widely. Empire BlueCross BlueShield, Aetna, and UnitedHealthcare each maintain separate PA criteria. A 2022 analysis published in the Journal of Women's Health found that women seeking HSDD pharmacotherapy faced PA denial rates of 28-34% on first submission, with the most common reason being insufficient documentation of distress [11]. Submitting the FSDS-R score alongside the PA form significantly reduces denial rates.

The list price for a single Vyleesi autoinjector (1.75 mg) is approximately $99 per dose through the manufacturer's patient assistance program. Without insurance and without assistance, a four-dose supply retails at roughly $800-$900 at major New York pharmacies. Palatin Technologies maintains a savings card program that may reduce out-of-pocket cost to $99 per prescription for eligible commercially insured patients [12].

Vyleesi Pharmacies in New York: Retail, Specialty, and 503A Compounding

Several pharmacy options exist for New York residents.

Retail and specialty pharmacies. CVS Specialty, Walgreens Specialty, and Rite Aid locations across New York can fill a Vyleesi prescription. The brand autoinjector requires cold-chain shipping and may need to be ordered in advance at a standard retail location.

503A compounding pharmacies. New York-licensed 503A pharmacies may compound bremelanotide for an individual patient based on a valid prescription, provided no commercially available product meets the patient's clinical need. The New York State Board of Pharmacy enforces 503A regulations consistent with USP Chapter 797 sterile compounding standards [13]. Compounded bremelanotide is not FDA-approved and is not substitutable for the branded Vyleesi autoinjector; however, it may be prepared in a lower-concentration formulation or an alternative delivery vehicle when medically justified and documented by the prescriber.

Compounded bremelanotide may be shipped to a New York address by any 503A pharmacy licensed in New York state. Out-of-state 503A pharmacies must hold a New York non-resident pharmacy license to ship into New York. 503B outsourcing facilities may not dispense directly to individual patients and are not a legal source for patient-specific Vyleesi compounding [14].

Mail-order options. Express Scripts and OptumRx process Vyleesi prescriptions for New York residents enrolled in their respective plans. Standard delivery is five to seven business days; expedited shipping is two to three business days.

Side Effects and Safety Considerations Relevant to New York Patients

Nausea is the most commonly reported adverse effect. In the RECONNECT trials, 40.0% of women in the bremelanotide arm reported nausea compared with 1.4% in the placebo arm [1]. Most episodes were mild-to-moderate and resolved within 30-60 minutes without treatment. Taking the injection while fasting increased nausea rates; a light snack one hour before dosing reduced but did not eliminate the effect.

Flushing affected 20.3% of bremelanotide-treated participants in RECONNECT versus 0% placebo [1]. Transient blood pressure elevation, headache, and focal hyperpigmentation (particularly with repeated use) round out the most frequent adverse effects documented in the FDA label [2].

Women with a history of migraine should discuss the headache risk with their New York prescriber before starting therapy. The American Migraine Foundation notes that any vasoactive agent can lower the threshold for a migraine attack in susceptible individuals [15].

Transferring a Vyleesi Prescription to New York

If you have an existing Vyleesi prescription from another state and relocate to New York, the prescription can be transferred to a New York pharmacy provided: the original prescriber held a valid license in the state of origin, the prescription was issued following a legitimate patient-provider relationship, and the transferred prescription meets New York prescription requirements (patient name, date, drug, dose, quantity, prescriber DEA or NPI, and directions) [16]. Bremelanotide is not a controlled substance, so DEA transfer restrictions do not apply. A 90-day supply may be transferred as a single fill.

If the original prescriber is not licensed in New York, the prescription cannot be renewed by that clinician. You would need a new New York-licensed prescriber to evaluate you and issue a new prescription. A HealthRX telehealth visit covers this scenario within one business day for most New York residents.

Comparing Vyleesi to Addyi (Flibanserin) for New York Patients

Both Vyleesi and Addyi (flibanserin 100 mg daily) are FDA-approved for acquired, generalized HSDD in premenopausal women, but they differ in mechanism, administration, and practical logistics that matter to New York patients.

Flibanserin is a daily oral serotonin receptor agonist/antagonist approved in 2015. It requires 8 weeks of continuous use before a therapeutic effect is expected, carries a black-box warning for severe hypotension with alcohol, and is available only through an FDA-required REMS program [17]. Bremelanotide is on-demand, requires no REMS, and produces measurable desire increases within 45 minutes of a single dose [1].

A head-to-head comparison has not been published. Clinicians often choose based on patient preference: women who prefer not to take a daily medication tend to favor Vyleesi; women with frequent sexual activity (more than once per 24 hours on any given day) may prefer flibanserin's continuous coverage.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states: "For premenopausal women with HSDD, we suggest offering either flibanserin or bremelanotide, with the choice guided by patient preference, dosing convenience, and individual risk factors" [18].

What to Expect at Your New York Vyleesi Visit

A first visit for Vyleesi in New York, whether in-person or via telehealth, typically covers six areas: symptom timeline and onset (acquired vs. Lifelong), relationship and psychosocial context, medical history with cardiovascular and hepatic focus, current medication review, validated screening tool completion, and blood pressure confirmation.

The visit lasts 20-30 minutes for telehealth and 30-45 minutes in office. No pelvic exam is required for the bremelanotide evaluation. A follow-up visit at 8-12 weeks is standard to assess response and tolerability; if nausea is unacceptable or efficacy is insufficient after three to four uses, the clinician may reassess the diagnosis or suggest an alternative treatment.

The North American Menopause Society (NAMS) 2022 hormone therapy position statement notes that HSDD evaluation should include a screen for genitourinary syndrome of menopause (GSM), which can coexist and may respond to topical estrogen independent of bremelanotide therapy [19]. A thorough New York provider will assess for both conditions in the same visit.

Frequently Asked Questions